For the time being, markets seem to be taking the U.S. attack on Iran as a blip. Whether that holds as the conflict goes on ...

Eli Lilly has announced its intention to acquire Verve Therapeutics, a biotechnology company specializing in gene-editing ...

HealthDay News — Drugmaker Eli Lilly plans to buy Verve Therapeutics, a gene-editing startup, for about $1 billion upfront. The deal gives Lilly a potential new treatment for heart disease, The Wall ...

A common blood test can flag early Alzheimer's disease patients who are four times more likely to experience rapid brain ...

People who have frequent nightmares appear to have a tripled risk of premature death, according to a new study.

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and ...

Wall Street’s major market averages seesawed back and forth on Friday and finished mixed as Federal Reserve Governor ...

Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to ...

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a ...

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...